Isarna Therapeutics
Munich
About Isarna Therapeutics
Isarna Therapeutics has an unmatched commitment to developing selective TGF-╬▓ inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $124.2M
- Last round: Series Unknown (Apr 2014)
- Website: isarna-therapeutics.com
- Phone: 49 89 890831 0
Industries & Categories
Biotechnology, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/isarna-therapeutics-379500 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.